Loading...
XNAS
VCRE
Market cap288mUSD
, Last price  
USD
Name

Vicore Pharma Holding AB

Chart & performance

D1W1MN
XNAS:VCRE chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
34.62%
Rev. gr., 5y
-11.73%
Revenues
4m
-96.51%
3,3143,305,0001,571,000840,000852,000932,000508,00000000109,346,0003,817,000
Net income
-477m
L+183.14%
-3,158-1,603,00013,687,000-4,570,000-6,652,000-12,855,000-21,681,000-93,084,000-146,862,000-296,481,000-288,422,000-310,942,000-168,634,000-477,474,000
CFO
-374m
L+127.00%
-1,669-1,793,000-2,825,000-3,682,000-7,251,000-7,705,000-33,036,000-86,999,000-119,935,000-265,171,000-299,919,000-249,583,000-164,946,000-374,435,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.
URL
https://vicorepharma.com/
IPO date
Dec 10, 2015
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT